362510-54-1 Usage
Classification
Synthetic compound
Belongs to the class of non-opioid analgesics
Primary use
Management of moderate to severe pain
Commonly used after surgery or for chronic conditions like arthritis
Mechanism of action
Inhibits the reuptake of certain neurotransmitters
In the central nervous system, this helps to alleviate pain
Advantages
Does not produce sedative or addictive effects
Valuable alternative for individuals who cannot tolerate or are at risk of opioid addiction
Onset of action
Relatively rapid
Tolerance
Well tolerated by most people
Common side effects
Dizziness, headache, and nausea
Caution
Should be exercised in individuals with certain medical conditions or those taking other medications
Due to possible interactions and adverse effects
Check Digit Verification of cas no
The CAS Registry Mumber 362510-54-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,2,5,1 and 0 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 362510-54:
(8*3)+(7*6)+(6*2)+(5*5)+(4*1)+(3*0)+(2*5)+(1*4)=121
121 % 10 = 1
So 362510-54-1 is a valid CAS Registry Number.
362510-54-1Relevant articles and documents
Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors
Yamashita, Dennis S.,Marquis, Robert W.,Xie, Ren,Nidamarthy, Sirishkumar D.,Oh, Hye-Ja,Jeong, Jae U.,Erhard, Karl F.,Ward, Keith W.,Roethke, Theresa J.,Smith, Brian R.,Cheng,Geng, Xiaoliu,Lin, Fan,Offen, Priscilla H.,Wang, Bing,Nevins, Neysa,Head, Martha S.,Haltiwanger, R. Curtis,Sarjeant, Amy A. Narducci,Liable-Sands, Louise M.,Zhao, Baoguang,Smith, Ward W.,Janson, Cheryl A.,Gao, Enoch,Tomaszek, Thaddeus,McQueney, Michael,James, Ian E.,Gress, Catherine J.,Zembryki, Denise L.,Lark, Michael W.,Veber, Daniel F.
, p. 1597 - 1612 (2007/10/03)
The syntheses, in vitro characterizations, and rat and monkey in vivo pharmacokinetic profiles of a series of 5-, 6-, and 7-methyl-substituted azepanone-based cathepsin K inhibitors are described. Depending on the particular regiochemical substitution and
